CCL17/TARC Antibody [Unconjugated]

Recombinant Human CCL17/TARC (Catalog #364‑DN) chemoattracts the BaF3 mouse pro‑B cell line transfected with human CCR4 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CCL17/TARC (0.01 µg/mL) is neutral­ized (green line) by increasing concentrations of Goat Anti-Human CCL17/TARC Antigen Affinity-purified Polyclonal Antibody (Catalog # AF364). The ND50 is typically 0.3-1.5 µg/mL.

CCL17/TARC was detected in immersion fixed paraffin-embedded sections of human spleen using Goat Anti-Human CCL17/TARC Antigen Affinity-purified Polyclonal Antibody (Catalog # AF364) at 10 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in lymphocytes. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Expression of CCL17 and the morphological transformation of renal tissues in UUO mice. (A) Kidney tissue of C57BL/6 mice with unilateral ureteral obstruction (UUO) for 7 and 14 days visualized by hematoxylin and eosin (H&E) stain, immunohistochemical stain (CCL-17, alpha -SMA, and vimentin), and Masson’s Trichrome staining; (B) qRTPCR and (C) western blot of mRNA and protein expressions of CCL17, collagen I, alpha -SMA, and vimentin in sham surgery and UUO mice. GAPDH was used to normalize mRNA loading. Results are expressed as the mean ± SD of at least three independent experiments. ** p < 0.01 compared with sham surgery group. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/34943853), licensed under a CC-BY license. Not internally tested by R&D Systems.

Expression of CCL17 and the morphological transformation of renal tissues in UUO mice. (A) Kidney tissue of C57BL/6 mice with unilateral ureteral obstruction (UUO) for 7 and 14 days visualized by hematoxylin and eosin (H&E) stain, immunohistochemical stain (CCL-17, alpha -SMA, and vimentin), and Masson’s Trichrome staining; (B) qRTPCR and (C) western blot of mRNA and protein expressions of CCL17, collagen I, alpha -SMA, and vimentin in sham surgery and UUO mice. GAPDH was used to normalize mRNA loading. Results are expressed as the mean ± SD of at least three independent experiments. ** p < 0.01 compared with sham surgery group. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/34943853), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu
• Applications: WB, IHC, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

CCL17/TARC Antibody [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant human CCL17/TARC (R&D Systems, Catalog # 364-DN)
  Ala24-Ser94
  Accession # Q92583
• Specificity: Detects human CCL17/TARC in direct ELISAs and Western blots. In direct ELISAs, approximately 20% cross-reactivity with recombinant mouse TARC is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: CCL17
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 5-15 ug/mL
  • Neutralization 0.3-1.5 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CCL17/TARC Antibody [Unconjugated]

• ABCD-2
• CC chemokine TARC
• C-C motif chemokine 17
• CCL17
• chemokine (C-C motif) ligand 17
• MGC138273
• SCYA17
• SCYA17MGC138271
• small inducible cytokine subfamily A (Cys-Cys), member 17
• Small-inducible cytokine A17
• T cell-directed CC chemokine
• TARC
• TARCA-152E5.3
• Thymus and activation-regulated chemokine

Background

CCL17 is a novel CC chemokine identified using a signal sequence trap method. CCL17 cDNA encodes a highly basic 94 amino acid (aa)residue precursor protein with a 23 aa residue signal peptide that is cleaved to generate the 71 aa residue mature secreted protein. Among CC chemokine family members, CCL17 has approximately 24-29% amino acid sequence identity with RANTES, MIP-1 alpha , MIP-1 beta , MCP-1, MCP-2, MCP-3, and I-309. The gene for human CCL17 has been mapped to chromosome 16q13 rather than chromosome 17 where the genes for many human CC chemokines are clustered. CCL17 is constitutively expressed in thymus, and at a lower level in lung, colon, and small intestine. CCL17 is also transiently expressed in stimulated peripheral blood mononuclear cells. Recombinant CCL17 has been shown to be chemotactic for T cell lines but not monocytes or neutrophils. CCL17 was identified to be a specific functional ligand for CCR4, a receptor that is selectively expressed on T cells.

1. Imai, T. et al. (1997) J. Biol. Chem. 272:15036.
2. Imai, T. et al. (1996) J. Biol. Chem. 271:21514.
3. Nomiyama, H. et al. (1997) Genomics 40:211.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CCL17/TARC Antibody (AF364)(13)

Publications using AF364

• J Driessen, MJ Kersten, L Visser, A van den Be, SH Tonino, JM Zijlstra, PJ Lugtenburg, F Morschhaus, M Hutchings, S Amorim, T Gastinne, M Nijland, GJC Zwezerijne, R Boellaard, HCW de Vet, AIJ Arens, R Valkema, RDK Liu, EEE Drees, D de Jong, WJ Plattel, A Diepstra, HOVON Lune Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP Leukemia, 2022-10-14;0(0):. 2022-10-14 [PMID: 36241696] (IHC, Human)
• YH Hsieh, WC Wang, TW Hung, CC Lee, JP Tsai C-C Motif Chemokine Ligand-17 as a Novel Biomarker and Regulator of Epithelial Mesenchymal Transition in Renal Fibrogenesis Cells, 2021-11-29;10(12):. 2021-11-29 [PMID: 34943853] (Western Blot, Human)
• Michael Kvorjak, Yasmine Ahmed, Michelle L. Miller, Raahul Sriram, Claudia Coronnello, Jana G. Hashash et al. Cross-talk between Colon Cells and Macrophages Increases ST6GALNAC1 and MUC1-sTn Expression in Ulcerative Colitis and Colitis-Associated Colon Cancer Cancer Immunology Research 2/1/2020 [PMID: 31831633]
• Rump L, Mattey D, Kehoe O, Middleton J An initial investigation into endothelial CC chemokine expression in the human rheumatoid synovium. Cytokine, 2017-09-01;97(0):133-140. 2017-09-01 [PMID: 28648867] (IHC-Fr, Human)
• Y Yuan, J Kluiver, J Koerts, D de Jong, B Rutgers, FRA Razak, M Terpstra, B Plaat, IM Nolte, A Diepstra, L Visser, K Kok, A van den Be miR-24-3p Is Overexpressed in Hodgkin Lymphoma and Protects Hodgkin and Reed-Sternberg Cells from Apoptosis Am. J. Pathol., 2017-04-20;0(0):. 2017-04-20 [PMID: 28432871] (IHC, Human)
• Oo YH, Weston CJ, Lalor PF, Curbishley SM, Withers DR, Reynolds GM, Shetty S, Harki J, Shaw JC, Eksteen B, Hubscher SG, Walker LS, Adams DH Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J. Immunol., 2010-02-17;184(6):2886-98. 2010-02-17 [PMID: 20164417] (IHC-P, Human)
• Kishi M, Miyazaki Y, Jinta T, Furusawa H, Ohtani Y, Inase N, Yoshizawa Y Pathogenesis of cBFL in common with IPF? Correlation of IP-10/TARC ratio with histological patterns. Thorax, 2008-02-14;63(9):810-6. 2008-02-14 [PMID: 18276722] (IHC-P, Human)
• Ma Y, Visser L, Roelofsen H, de Vries M, Diepstra A, van Imhoff G, van der Wal T, Luinge M, Alvarez-Llamas G, Vos H, Poppema S, Vonk R, Van Den Berg A Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood, 2007-12-10;111(4):2339-46. 2007-12-10 [PMID: 18070985] (IHC-P, Human)
• Heijink IH, Kies PM, Kauffman HF, Postma DS, van Oosterhout AJ, Vellenga E Down-regulation of E-cadherin in human bronchial epithelial cells leads to epidermal growth factor receptor-dependent Th2 cell-promoting activity. J. Immunol., 2007-06-15;178(12):7678-85. 2007-06-15 [PMID: 17548604] (ICC, Human)
• Rust R, Kluiver J, Visser L, Harms G, Blokzijl T, Kamps W, Poppema S, Van Den Berg A Gene expression analysis of dendritic/Langerhans cells and Langerhans cell histiocytosis. J. Pathol., 2006-08-01;209(4):474-83. 2006-08-01 [PMID: 16718746] (IHC, Human)
• Vestergaard C, Johansen C, Christensen U, Just H, Hohwy T, Deleuran M TARC augments TNF-alpha-induced CTACK production in keratinocytes. Exp. Dermatol., 2004-09-01;13(9):551-7. 2004-09-01 [PMID: 15335355] (Human)
• Ohshima K, Karube K, Kawano R, Tsuchiya T, Suefuji H, Yamaguchi T, Suzumiya J, Kikuchii M Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: Analysis of prognosis. Int. J. Oncol., 2004-09-01;25(3):605-13. 2004-09-01 [PMID: 15289861] (IHC-P, Human)
• Maggio EM, Van Den Berg A, Visser L, Diepstra A, Kluiver J, Emmens R, Poppema S Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical Hodgkin lymphomas. Int. J. Cancer, 2002-06-10;99(5):665-72. 2002-06-10 [PMID: 12115499] (ICC, IHC, Human)

Bioinformatics

• Gene Symbol: CCL17
• Uniprot:
  • Q92583()